Tony Hitchcock | 03/22/2016
When we look at the current trends with what we can refer to as “next generation therapeutics”, whether it be ADCs or cell and gene therapy products, one trend is very clear, products are becoming increasingly complex in their nature. Certainly, the complexity of the manufacturing processes used to produce them clearly reflects this; hand in hand with ever increasing product development costs and timelines. Many of these products are being developed by small start-up companies frequently funded...
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More